Detalhe da pesquisa
1.
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses.
Immunity
; 54(4): 769-780.e6, 2021 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33823129
2.
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
N Engl J Med
; 387(5): 397-407, 2022 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921449
3.
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Lancet
; 401(10373): 294-302, 2023 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709074
4.
A Monoclonal Antibody for Malaria Prevention.
N Engl J Med
; 385(9): 803-814, 2021 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34379916
5.
Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans.
J Infect Dis
; 224(9): 1550-1555, 2021 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33961055
6.
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Lancet
; 393(10174): 889-898, 2019 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30686586
7.
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.
N Engl J Med
; 386(11): 1088-1091, 2022 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081298
8.
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
Lancet
; 391(10120): 552-562, 2018 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29217376
9.
Clonal hematopoiesis is not significantly associated with COVID-19 disease severity.
Blood
; 140(14): 1650-1655, 2022 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839449
10.
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
PLoS Med
; 15(1): e1002493, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29364886
11.
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.
JCI Insight
; 9(7)2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587079
12.
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
Lancet Infect Dis
; 23(5): 578-588, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708738
13.
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
Sci Transl Med
; 15(692): eade4790, 2023 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37075129
14.
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Lancet Infect Dis
; 23(12): 1408-1417, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37544326
15.
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.
J Acquir Immune Defic Syndr
; 89(4): 405-413, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34923559
16.
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
Nat Med
; 28(2): 383-391, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35115706
17.
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Nat Med
; 28(5): 1022-1030, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411076
18.
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.
EClinicalMedicine
; 48: 101477, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35783486
19.
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
Lancet Respir Med
; 9(10): 1111-1120, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33864736
20.
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.
medRxiv
; 2021 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931200